Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Switzerland | Healthcare | Pharmaceuticals | CHF 643.74B | 118.9x | 16.68 | CHF 830 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Roche Holding | Switzerland | Healthcare | Pharmaceuticals | CHF 248.26B | 21.5x | -2.83 | CHF 312 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Roche Holding Participation | Switzerland | Healthcare | Pharmaceuticals | CHF 227.61B | 23.4x | -2.85 | CHF 286 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Novartis | Switzerland | Healthcare | Pharmaceuticals | CHF 197.13B | 14x | 0.18 | CHF 97.45 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Novartis | Switzerland | Healthcare | Pharmaceuticals | CHF 196.24B | 22.1x | 0.18 | CHF 97.52 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Sandoz | Switzerland | Healthcare | Pharmaceuticals | CHF 15.05B | 229.3x | -2.39 | CHF 35.91 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Siegfried Holding Ltd | Switzerland | Healthcare | Pharmaceuticals | CHF 4.33B | 38.1x | -1.37 | CHF 1,012 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Galenica Sante | Switzerland | Healthcare | Pharmaceuticals | CHF 3.80B | 13.3x | 0.31 | CHF 76.15 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Dottikon Es Holding AG | Switzerland | Healthcare | Pharmaceuticals | CHF 3.50B | 43.3x | -5.34 | CHF 254.50 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Joincare Pharmaceutical DRC | Switzerland | Healthcare | Pharmaceuticals | CHF 2.41B | 17x | -2.69 | CHF 7.27 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
COSMO Pharma | Switzerland | Healthcare | Pharmaceuticals | CHF 1.13B | -240.3x | 1.78 | CHF 70.60 | 4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
PolyPeptide Group AG | Switzerland | Healthcare | Pharmaceuticals | CHF 929.74M | -19.9x | 0.02 | CHF 29.10 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Newron Pharmaceuticals | Switzerland | Healthcare | Pharmaceuticals | CHF 150.48M | -9.1x | -1.32 | CHF 8.02 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Santhera Pharmaceuticals Holding | Switzerland | Healthcare | Pharmaceuticals | CHF 85.05M | 1.8x | 0.01 | CHF 9.23 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Spexis | Switzerland | Healthcare | Pharmaceuticals | CHF 4.06M | -0.2x | -0.04 | CHF 0.06 | 20% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |